Heavy Drinking Can Damage Every Part of the Eye
Jun 24, 2022 · Those who drink heavily can develop peripheral neuropathy, which in turn may decrease corneal sensitivity, masking the real severity of dry eye. Researchers behind that study say their findings “indicate that controlling alcohol consumption may help to reduce [dry eye] prevalence.” 9. Sight-Threatening Diseases.
Ocular Myasthenia Gravis Treatment Options Explained
July 20, 2023. Myasthenia gravis (MG) can occur in 2 forms: a generalized myasthenia gravis (GMG) or purely ocular myasthenia gravis (OMG). Ocular myasthenia gravis is characterized by progressive fatigability of skeletal muscle limited to the orbicularis oculi, levator palpebrae superioris, and the extraocular muscles. 1 Up to half of patients ...
Homepage - Ophthalmology Advisor
By Alan P. Lyss, MD. Factors preventing more widespread use of biosimilars in oncology include the cost and complexity of biosimilar development, oncologists’ lack of knowledge about biosimilars, and the fact that interactions between payers, manufacturers, and pharmacy benefit managers can sometimes drive up the cost of biosimilars.
Topical 5-Fluorouracil Appropriate for Most Ocular Surface …
Jan 9, 2023 · Most patients with ocular surface squamous neoplasia (OSSN) respond to treatment with topical 5-fluorouracil (5FU) eye drops, with complete resolution achieved in 87% of eyes treated, according to results of a study published in The Ocular Surface.The study shows efficacy in 2 years worth of follow up with minimal side effects.
Restoring the Retina: Coming Advancements to Repair Structure …
Feb 16, 2021 · Retinal implants capture light and stimulate secondary neurons that have remained in the retina, such as ganglion cells and bipolar cells, which then send signals to the brain through the optic nerve. “Patients who get a retinal implant will see at least flashes of light,” says Gislin Dagnelie, PhD, associate professor of ophthalmology at ...
Biosimilar to Aflibercept Trial Shows Clinical Utility in nAMD ...
Jul 23, 2024 · The biosimilar to aflibercept candidate, ABP 938, has shown similar clinical efficacy, safety, and immunogenicity to aflibercept in the treatment of neovascular age-related macular degeneration (nAMD), according to a poster presented at the American Society of Retina Specialists meeting, held in Stockholm, July 17 to July 20, 2024.. Researcher Scott Friedman, MD led a team of researchers to ...
A 10-Year Follow-up Affirms AREDS2 with Lutein Still Effective, Safe
Jun 21, 2022 · Now, after 10 years, a follow-up analysis demonstrates lutein’s benefit continued without raising the risk for lung cancer, offering assurance for clinicians, as published in JAMA Ophthalmology. In AREDS2, a 5-year clinical trial, patients with intermediate AMD or late AMD in 1 eye were randomized to 4 treatment groups: lutein/zeaxanthin, ω ...
Endothelial Protection Better With DALK Than PKP
Feb 12, 2024 · On the other hand, the success rate for PKP was initially 100.0% at the 5-year mark but gradually declined to 63.8% at the 10-year mark. The difference in rejection-free survival rates between the two groups was significant. PKP rates were at 96.2% at 1, 80.1% at 2, and 67.1% at 5 years, compared with DALK rates of 96.6% at the same time points.
An Updated Keratoconus Screening Protocol for 2022
January 7, 2022. Diagnosing patients early in their disease course is the best-case scenario in most conditions, and keratoconus is no exception. Finding keratoconic eyes before progression steals vision, so those eyes can be successfully treated with therapies such as corneal cross-linking (CXL), is the goal.
Vision Quality With Trifocal IOL Rated High Despite Occasional …
Aug 23, 2021 · In Quality of Vision surveys, some “moderate” or “severe” visual disturbances were reported in the study population: halos for 12 (41.4%), starbursts in 4 (13.8%), and glare for 3 (10.3%). At the more “bothersome” 2 of 4 rating levels, 6 described halos, 3 had glare, and 2 noted starbursts. PanOptix is the only trifocal IOL ...